When photoreceptor cells in the retina begin to die, a silent molecular shift takes place—one that scientists at Scripps Research in La Jolla have now captured in striking detail. In a discovery that reframes how we understand the eye’s response to damage, the team found that erucamide, a little-studied molecule naturally present in the body, plays a crucial role in stabilizing the retina during degeneration. This breakthrough, published in Nature Neuroscience and developed in collaboration with UC San Diego and the Lowy Medical Research Institute, opens a new path for treating diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration—conditions that collectively affect millions and often lead to irreversible vision loss.
For decades, retinal degeneration has been viewed as a one-way decline. But the Scripps team, led by senior author Martin Friedlander, uncovered evidence that the retina is not a passive victim. Instead, it actively fights back. Using mass spectrometry-based metabolomics, they scanned the molecular landscape of retinal tissue across multiple preclinical models and noticed a sharp drop in erucamide levels as photoreceptors deteriorated. That decline wasn’t just a side effect—it was a signal. “The retina doesn’t simply deteriorate; in fact, it actively responds to injury,” Friedlander says. “Our work identifies erucamide as a signaling molecule that helps coordinate that response.”
Erucamide belongs to a class of lipid-like compounds, long known to act as cellular messengers but poorly understood in eye health. To test its potential, the researchers turned to porous silicon nanoparticles—tiny delivery vehicles engineered to release erucamide steadily and prevent it from clumping, a challenge due to the molecule’s hydrophobic nature. When reintroduced, erucamide didn’t target dying photoreceptors directly. Instead, it activated CD11b+ myeloid cells, immune sentinels in the retina that respond to injury. These cells, once stimulated, released signals that supported neurovascular stability—protecting both neurons and the delicate blood vessels that sustain them.
The team also identified TMEM19, a previously obscure protein, as the molecular docking site for erucamide. When TMEM19 levels were reduced, the protective cascade failed, confirming its essential role. This specificity suggests a precise biological pathway that could be harnessed therapeutically. While still in preclinical stages, the findings point to a future where vision loss might be slowed not by replacing cells, but by amplifying the eye’s innate resilience. As Dale Boger, co-author and Cramer Professor of Chemistry at Scripps, recalls: “It raised the possibility that erucamide could be influencing how tissue responds and wasn’t just changing as a consequence of disease.” With further development, this natural molecule might one day help millions hold onto the world they see.